We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
The shortages were declared in August 2022. Meanwhile, Axios reports on how makers of copycat weight loss drugs are preparing for a crackdown. In medical tech and pharma news: a pacemaker recall, the ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
4h
Axios on MSNCopycat Ozempic makers brace for crackdownMakers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
Uber CEO Dara Khosrowshahi says Tesla will go it alone at the start of its self-driving robotaxi journey. The Singapore-based company expects to raise $2.58 billion from the sale of its remaining ...
These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.
The shocking rise in health complications linked to weight-loss drugs like Ozempic has ignited a fierce debate about the efficacy and safety of these medications. Originally designed as diabetes ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...
The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency first ...
Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results